Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)

• Published in: Gut Vol. 68; no. 1; pp. 40 - 48
• Main Authors: Danese, Silvio, Vermeire, Séverine, Hellstern, Paul, Panaccione, Remo, Rogler, Gerhard, Fraser, Gerald, Kohn, Anna, Desreumaux, Pierre, Leong, Rupert W, Comer, Gail M, Cataldi, Fabio, Banerjee, Anindita, Maguire, Mary K, Li, Cheryl, Rath, Natalie, Beebe, Jean, Schreiber, Stefan
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.01.2019; BMJ Publishing Group
• Series: Original article
• Subjects: Apoptosis; Clinical medicine; Clinical trials; Crohn's disease; Cytokines; Employees; Gangrene; Gastroenterology; Immunoglobulins; Inflammation; Inflammatory Bowel Disease; Interleukin 6; Lupus; Pain; Patients; R&D; Remission; Research & development; Rheumatoid arthritis; Rhinopharyngitis; Studies; Tumor necrosis factor; Tumor necrosis factor-TNF; Tumors; inadequate response; anti-IL6 antibody; crohn’s disease; anti-TNF

ObjectiveNeutralising pro-inflammatory interleukin-6 (IL-6) may effectively treat Crohn’s disease (CD). Effects of PF-04236921, an anti-IL-6 antibody, in adults with CD are reported.DesignParallel-group, dose-ranging, double-blind trial with 4-week screening and 12-week treatment periods. After indu...